Since PD-L1 is a suboptimal predictor of ICI efficacy, several other potential biomarkers have been proposed, including tumor mutational burden,12 infiltration of the tumor stroma by T-lymphocytes and other immune cell effectors13 and molecular signatures involving clusters of genes related to inflammation, such as interferon-γ cluster gene expression.14 The gene discussed is CD274; the disease is neoplasm.